ArticleScientific reports2026
Piperazine linked chitosan schiff base nanoparticles as a novel antibiofilm and antibacterial strategy against clinically relevant pathogens.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of multifunctional antimicrobial materials capable of targeting both planktonic bacteria and biofilm-associated infections remains a critical challenge in combating antimicrobial resistance. In this study, a novel piperazine-linked chitosan Schiff base (Cs-TPA-PiP) and its ionically crosslinked nanoparticle formulation (Cs-TPA-PiP NPs) were synthesized and structurally characterized. The antimicrobial potential of both Cs-TPA-PiP and Cs-TPA-PiP NPs was evaluated against a panel of nine standard clinically significant bacterial strains. The compounds demonstrated significant and broad-spectrum antibacterial activity. The minimum inhibitory concentration (MIC) values demonstrated potent efficacy, with Cs-TPA-PiP and its Cs-TPA-PiP NPs ranging from 0.63 to 2.50 mg/mL and 1.00-5.00 mg/mL, respectively. Notably, both agents exhibited a strong dose-dependent inhibitory effect on biofilm formation. While Cs-TPA-PiP showed lower MIC values against planktonic cells, the corresponding Cs-TPA-PiP NPs with an ultra-small spherical size of 15.6 nm exhibited superior antibiofilm performance, ranging from 73.00% to 95.00% inhibition of biofilm biomass at 1× MIC in strong biofilm-producing strains. Transmission electron microscopy (TEM) confirmed severe morphological alterations and membrane disruption in treated bacterial cells, consistent with a membrane-targeting mechanism. In silico molecular docking studies suggested that the compound has favorable binding affinity for the critical bacterial cell wall target, Sortase A, thereby identifying it as a potential theoretical target requiring further validation. Our findings collectively establish Cs-TPA-PiP and its Cs-TPA-PiP NPs as effective antibacterial and anti-biofilm candidates, with their activity primarily attributed to membrane disruption. The proposed role of Sortase A inhibition remains hypothetical and warrants further investigation. These findings highlight their potential as multifunctional antibacterial platforms for managing biofilm-associated and resistant bacterial infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.